Identifying a new blood cancer to improve the outlook for leukaemia patients
Looking at a new subtype of leukaemia, called CML-like Ph+ALL, to see how best to diagnose and treat it.
Understanding why some childhood blood cancers are incurable
Using models to find out how high risk leukaemia cells grow and become resistant to treatment.
How do leukaemia stem cells talk to the immune system in juvenile myelomonocytic leukaemia?
Find out how JMML cells are able to switch off the immune system, causing relapse.
What factors affect the survival of children and young people with high-risk acute lymphoblastic leukaemia?
Finding out what makes ALL more high-risk, such as age of diagnosis or type of initial treatment.
Investigating clinical trial samples to predict how atypical teratoid rhabdoid tumours will respond to treatment
Looking at cancer samples to find markers that can predict how a child's cancer will respond to treatment.
Creating a new immunotherapy approach to fight aggressive medulloblastoma
Finding a way to use immunotherapy against a high-risk type of childhood brain tumour.
Confirming bloodstream markers of children’s kidney cancer
Identifying markers that can be used for a non-invasive test to diagnose and monitor Wilms tumour.
Repurposing alcohol-abuse medicines to treat brain tumours
Understanding how a repurposed drug attacks and kills diffuse midline glioma cells.
Stopping drug resistant processes in T-cell acute lymphoblastic leukaemia
Developing a test to select patients who can be treated with a new medicine that prevents steroid resistance.